Literature DB >> 25231275

Primary thromboprophylaxis in patients with solid cancers.

Nay Min Tun1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25231275     DOI： 10.1007/s11239-014-1138-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  9 in total

1.  Efficacy vs effectiveness.

Authors:  Charlene Compher
Journal:  JPEN J Parenter Enteral Nutr       Date:  2010 Nov-Dec       Impact factor: 4.016

2.  Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.

Authors:  Sylvia K Haas; Mathias Freund; David Heigener; Lothar Heilmann; Bettina Kemkes-Matthes; Georg-Friedrich von Tempelhoff; Nima Melzer; Ajay K Kakkar
Journal:  Clin Appl Thromb Hemost       Date:  2012-01-23       Impact factor: 2.389

Review 3.  Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis.

Authors:  Pooja Chaukiyal; Amit Nautiyal; Sangeetha Radhakrishnan; Sonal Singh; Sankar D Navaneethan
Journal:  Thromb Haemost       Date:  2008-01       Impact factor: 5.249

4.  When to use the odds ratio or the relative risk?

Authors:  Carsten Oliver Schmidt; Thomas Kohlmann
Journal:  Int J Public Health       Date:  2008       Impact factor: 3.380

Review 5.  Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis.

Authors:  Minh Phan; Sonia John; Ana I Casanegra; Suman Rathbun; Aaron Mansfield; Julie A Stoner; Alfonso J Tafur
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

6.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Authors:  A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

7.  Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial.

Authors:  Annie M Young; Lucinda J Billingham; Gulnaz Begum; David J Kerr; Ana I Hughes; Daniel W Rea; Stephen Shepherd; Andrew Stanley; Ann Sweeney; Jonathan Wilde; Keith Wheatley
Journal:  Lancet       Date:  2009-02-14       Impact factor: 79.321

Review 8.  Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.

Authors:  Elie A Akl; Ganesh Kamath; Victor Yosuico; Seo Young Kim; Maddalena Barba; Francesca Sperati; Deborah J Cook; Holger J Schünemann
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

9.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.